Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Mebanks Divests Guangzhou Specialty Pharmacy Subsidiary to DaShenLin for $7.75 Million to Focus on Higher-Margin Health Insurance and Management Businesses

Fineline Cube Apr 23, 2026
Company Deals

AbbVie Announces $1.4 Billion Advanced Manufacturing Campus in North Carolina to Support Immunology, Neuroscience, and Oncology Portfolio

Fineline Cube Apr 23, 2026
Company Deals Digital

Merck & Co. Announces $1 Billion Strategic Partnership with Google Cloud to Deploy Enterprise-Wide Agentic AI Platform

Fineline Cube Apr 23, 2026
Company Deals

Boji Medical Sells Fluconazole Ear Drops Technology to Chengdu Pusch for $2M

Fineline Cube Apr 22, 2026
Company Deals

Novabio Therapeutics and OBiO Tech Strengthen Partnership to Advance Treg Cell Therapies for Neurodegenerative Diseases

Fineline Cube Apr 22, 2026
Policy / Regulatory

NMPA Suspends Colchicine API Imports from Indian Manufacturers Alkaloids Bioactives and Alchem International Over Change Management Violations

Fineline Cube Apr 23, 2026
Company Drug

Transcenta Presents Promising Pre-clinical Data for Proprietary LIV1 Antibody-Drug Conjugate at AACR 2026

Fineline Cube Apr 23, 2026
Company Drug

Simcere Pharmaceutical Withdraws NDA for Rademikibart in Atopic Dermatitis, Plans Resubmission Later This Month

Fineline Cube Apr 23, 2026
Company Drug

Keymed Biosciences Gains NMPA Approval for Phase I/II Study of CM518D1

Fineline Cube Apr 27, 2025

China-based Keymed Biosciences Inc. (HKG: 2162) announced that it has received approval from the National...

Company Drug

Akeso’s Ivonescimab Approved by NMPA for First-Line PD-L1-Positive NSCLC

Fineline Cube Apr 27, 2025

China-based Akeso, Inc. (HKG: 9926) announced that its supplementary New Drug Application (sNDA) for ivonescimab,...

Company Drug

Hefei Lifeon Gains NMPA Approval for Nexletol Clinical Trials in China

Fineline Cube Apr 26, 2025

China-based Hefei Lifeon Pharmaceutical Co., Ltd (SHE: 003020) announced that it has received clinical trial...

Company Drug

Fujian Cosunter Gains NMPA Clearance for Phase II HBV Study of GST-HG131 and GST-HG141

Fineline Cube Apr 26, 2025

China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) announced that it has received clearance from...

Company Drug

Anhui Anke’s Allogeneic CAR-T Therapy UTAA09 Approved for r/r B-ALL Trials

Fineline Cube Apr 25, 2025

China-based Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009) announced that its joint venture with...

Company Drug

Juventas Cell Therapy’s CNCT 19 Gains NMPA Approval for Refractory Lupus Nephritis

Fineline Cube Apr 25, 2025

China-based Juventas Cell Therapy Ltd announced that its chimeric antigen receptor (CAR)-T cell therapy, inaticabtagene...

Company Drug

TYK Medicines Submits Pre-NDA Package for Asandeutertinib in NSCLC Brain Metastasis

Fineline Cube Apr 25, 2025

China-based TYK Medicines, Inc. (HKG: 2410) announced the formal submission of a pre-NDA communication package...

Company Medical Device

MicroPort Scientific’s MRI-Conditional ALIZEA Hybrid Pacing System Secures CE Certification

Fineline Cube Apr 25, 2025

Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853), through its French subsidiary MicroPort Cardiac...

Company Drug

AbbVie Files BLA for TrenibotE in Moderate to Severe Glabellar Lines Treatment

Fineline Cube Apr 25, 2025

US-based AbbVie (NYSE: ABBV) announced that it has filed a Biologics License Application (BLA) with...

Company Drug

GenFleet’s KRAS G12D Inhibitor GFH375/VS-7375 Gains FDA Trial Approval

Fineline Cube Apr 25, 2025

Shanghai-based biotech GenFleet Therapeutics announced that its GFH375/VS-7375, an oral KRAS G12D inhibitor co-developed with...

Company Deals Drug

Innate Pharma and Sanofi Restructure 2016 Research Agreement on CD123 ANKET Drug

Fineline Cube Apr 25, 2025

France-based Innate Pharma SA has announced a significant adjustment to its 2016 research and licensing...

Company Medical Device

Medtronic Submits 510(k) Applications for Interoperable Diabetes Management System

Fineline Cube Apr 25, 2025

US-Irish firm Medtronic plc (NYSE: MDT) has submitted twin 510(k) applications to the U.S. Food...

Company Medical Device

Thermo Fisher Announces $2 Billion US Investment to Strengthen Life Sciences Infrastructure

Fineline Cube Apr 25, 2025

US-based life sciences giant Thermo Fisher Scientific Inc. (NYSE: TMO) has announced a USD 2...

Company Deals

Merck KGaA Nears Completion of $3.5 Billion Acquisition of SpringWorks Therapeutics

Fineline Cube Apr 25, 2025

German pharmaceutical major Merck KGaA (ETR: MRK) is reportedly nearing the completion of its acquisition of...

Company Deals

CN Bio and Pharmaron Partner to Validate and Expand OOC Technology Applications

Fineline Cube Apr 25, 2025

CN Bio, a UK-based provider of Organ-on-a-chip (OOC) systems and solutions, has entered into a...

Company

Gan & Lee Pharmaceuticals Reports 417 Million USD Revenue and 80.75% Profit Surge in 2024

Fineline Cube Apr 25, 2025

Gan & Lee Pharmaceuticals (SHA: 603087) reported revenues of RMB 3.045 billion (USD 417 million)...

Company Drug

Hepalink Secures SAHPRA Approval for Ivenoxin in South Africa

Fineline Cube Apr 25, 2025

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SHE: 002399, HKG: 9989) has announced that it has...

Company Drug

Akeso’s Penpulimab Gains FDA Approval for Nasopharyngeal Carcinoma Treatment

Fineline Cube Apr 25, 2025

China-based Akeso, Inc. (HKG: 9926) announced that it has received marketing approval from the US...

Company

Sanofi Reports Q1 Sales Growth Driven by Dupixent and New Product Launches

Fineline Cube Apr 25, 2025

French pharmaceutical giant Sanofi (NASDAQ: SNY) released its Q1 2025 financial results, reporting global net...

Company Deals

Shineco Inc. Announces Acquisition of InfiniClone for Regenerative Medicine Expansion

Fineline Cube Apr 24, 2025

US-based Shineco Inc. (NASDAQ: SISI) announced that its subsidiary Shineco Life Sciences Group Hong Kong...

Posts pagination

1 … 161 162 163 … 656

Recent updates

  • Transcenta Presents Promising Pre-clinical Data for Proprietary LIV1 Antibody-Drug Conjugate at AACR 2026
  • Simcere Pharmaceutical Withdraws NDA for Rademikibart in Atopic Dermatitis, Plans Resubmission Later This Month
  • Hengrui Pharmaceuticals Reports Strong Q1 2026 Results with 12.98% Revenue Growth and Multiple New Drug Approvals
  • Mebanks Divests Guangzhou Specialty Pharmacy Subsidiary to DaShenLin for $7.75 Million to Focus on Higher-Margin Health Insurance and Management Businesses
  • Kangtai Biological Initiates Phase I Clinical Study for Trivalent Influenza Split Vaccine Produced in MDCK Cells
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Transcenta Presents Promising Pre-clinical Data for Proprietary LIV1 Antibody-Drug Conjugate at AACR 2026

Company Drug

Simcere Pharmaceutical Withdraws NDA for Rademikibart in Atopic Dermatitis, Plans Resubmission Later This Month

Company

Hengrui Pharmaceuticals Reports Strong Q1 2026 Results with 12.98% Revenue Growth and Multiple New Drug Approvals

Company Deals

Mebanks Divests Guangzhou Specialty Pharmacy Subsidiary to DaShenLin for $7.75 Million to Focus on Higher-Margin Health Insurance and Management Businesses

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.